Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic hematopoietic stem cell transplant (Masonic Cancer Center)
- Development stage
- Unknown
- Lead developer
- Masonic Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This therapeutic intervention refers to allogeneic hematopoietic stem cell transplantation (HSCT) using unrelated or partially matched donors, as investigated by the Masonic Cancer Center at the University of Minnesota. The protocol is designed for patients with previously treated lymphoma, multiple myeloma, or chronic lymphocytic leukemia. The procedure involves a conditioning regimen of chemotherapy (busulfan and cyclophosphamide) and total body irradiation to eradicate malignant cells and prevent graft rejection. Following conditioning, donor-derived stem cells (from bone marrow or umbilical cord blood) are infused to reconstitute the patient's hematopoietic system and induce a graft-versus-tumor (GVT) effect, where donor immune cells target residual cancer. Post-transplant immunosuppression with agents like methotrexate and cyclosporine is typically employed to mitigate graft-versus-host disease (GVHD).
- Other names
- Unrelated donor stem cell transplantPartially matched donor stem cell transplantAllo-HSCTstem cell-Masonic Cancer Center, University of Minnesota-lymphoma-multiple myeloma-chronic lymphocytic leukemia
Beyond the preview
Go deeper on Allogeneic hematopoietic stem cell transplant (Masonic Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic hematopoietic stem cell transplant (Masonic Cancer Center).